Hopfner Robert Lorne

EVMN Director Hopfner bought 1,000 shares at $17.35; stock now $17.11, -22.0% from 52-week high

Director Robert Lorne Hopfner purchased 1,000 shares of Evommune at $17.35, increasing his holdings from 3,026 to 4,026 shares. The company is unprofitable with net income of $-12.5M against quarterly revenue of $10.0M, while the stock trades 22.0% below its 52-week high of $21.93. Hopfner's cross-ticker track record shows 4 prior buys with an average 90-day return of -31.3% and a 0% win rate, providing context on the historical outcome pattern of his open-market purchases. This purchase occurs in a declining-price environment without any material corporate developments disclosed in the filing to explain the timing.